Proficio Capital Partners LLC Makes New $1.59 Million Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Proficio Capital Partners LLC bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 19,043 shares of the biopharmaceutical company's stock, valued at approximately $1,590,000.

Several other institutional investors also recently bought and sold shares of ITCI. Avior Wealth Management LLC raised its holdings in shares of Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock worth $327,000 after buying an additional 131 shares during the last quarter. M&T Bank Corp raised its holdings in shares of Intra-Cellular Therapies by 2.2% in the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company's stock worth $526,000 after buying an additional 138 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock worth $748,000 after buying an additional 141 shares during the last quarter. CIBC Asset Management Inc raised its holdings in shares of Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company's stock worth $247,000 after buying an additional 150 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its holdings in shares of Intra-Cellular Therapies by 6.4% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock worth $266,000 after buying an additional 192 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently issued reports on ITCI. Leerink Partnrs cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Piper Sandler reissued a "neutral" rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock traded up $0.05 on Friday, reaching $131.65. The company had a trading volume of 1,836,929 shares, compared to its average volume of 1,339,146. The firm's 50 day moving average price is $128.61 and its two-hundred day moving average price is $97.59. The firm has a market cap of $14.00 billion, a PE ratio of -151.32 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.67.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.